$83.00
▲ +1.0% Today
as of Jul 22, 16:48 ET
Last 30 days
Recent Press Releases & News
CYTK: Lowering target price to $85.00
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy
Overview
52-week range
$32
$80
100% of range
Avg surprise (last 3)
+6.7%
Avg reaction (last 2)
+4.7%
50% positive
Latest IV / EM
62%
EM ±14.2% · $80 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 5, 2026 | Mar/2026 | $-1.67 | $-1.67 | 0.0% | -22.8% | +16.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-2.55 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-1.12 | $-1.34 | +16.4% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $-1.36 | $-1.41 | +3.5% | — | -7.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.36 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.31 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.33 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-1.35 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.34 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$1.64 | -$1.12 | -46.4% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-184M | — | $-167M | $-112M | $-156M | — | $-141M | $-130M |
| Net income | $-206M | — | $-306M | $-134M | $-161M | — | $-161M | $-143M |
| EPS (diluted) | $-1.67 | — | $-2.55 | $-1.12 | $-1.36 | — | $-1.36 | $-1.31 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $130M | $123M | $225M | $75M | $74M | $95M | $47M | $190M |
| Inventory | $154,000 | $0 | — | — | — | — | — | — |
| Total current assets | $839M | $917M | $977M | $887M | $956M | $1.11B | $1.02B | $1.07B |
| Total assets | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B |
| Long-term debt | $247M | $246M | $159M | $159M | $92M | $93M | $93M | $93M |
| Total liabilities | $2.10B | $2.08B | $1.96B | $1.59B | $1.53B | $1.54B | $1.45B | $1.42B |
| Total equity | $-827M | $-660M | $-521M | $-369M | $-266M | $-135M | $-14M | $109M |